December 09, 2019
Weil is advising Sanofi in its definitive agreement with Synthorx, under which Sanofi will acquire all of the outstanding shares of Synthorx for approximately $2.5 billion. Synthorx is a clinical-stage biotechnology company focused on prolonging and improving the lives of people with cancer and autoimmune disorders. The transaction is expected to close in the first quarter of 2020, subject to the satisfaction or waiver of customary closing conditions.
The Weil team advising Sanofi is led by Mergers & Acquisitions partner Michael J. Aiello and includes Mergers & Acquisitions partner Amanda Fenster (elected partner effective January 1, 2020), Mergers & Acquisitions associates Stephen Liebscher, Samuel Son and Karl de la Roche (Not Yet Admitted in New York). The team also includes Head of Technology & IP Transactions Michael Epstein; Tax partner Devon Bodoh; Head of Executive Compensation & Benefits Paul Wessel; Antitrust/Competition partner John Scribner; Co-Head of Patent Litigation and Life Sciences Elizabeth Weiswasser; International Arbitration & Trade partner Ted Posner; Cybersecurity, Data Privacy & Information Management Co-Head Randi Singer; Technology & IP Transactions associates Kane Wishart, Rami Sherman and Caleb Small (Not Yet Admitted in New York); Tax associates Steven Ort and Jesse Hong; Executive Compensation & Benefits associate Daniel Rios; and Patent Litigation associates Natalie Kennedy, Andrew Gesior and Saif Askar (Not Yet Admitted in New York).